middle.news
Anteris Secures $290M Boost with Medtronic Backing for Heart Valve Trials
8:46am on Wednesday 21st of January, 2026 AEDT
•
Healthcare
Read Story
Anteris Secures $290M Boost with Medtronic Backing for Heart Valve Trials
8:46am on Wednesday 21st of January, 2026 AEDT
Key Points
Proposed $200 million public offering of common stock
Medtronic to invest up to $90 million via private placement
Funds to support DurAVR Transcatheter Heart Valve pivotal trial
Expansion of manufacturing capabilities and R&D funding
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anteris Technologies Global (ASX:AVR)
OPEN ARTICLE